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ABSTRACT
Purpose: This study aimed to estimate the prevalence, prescription pattern and burden of 
pediatric asthma in Korea by analyzing the National Health Insurance (NHI) claims data.
Methods: We retrospectively analyzed the insurance claim records from the Korean NHI claims 
database from January 2010 to December 2014. Asthmatic patients were defined as children 
younger than 18 years, with appropriate 10th Revision of the International Classification of 
Diseases codes (J45 or J46) and a prescription for 1 or more asthma maintenance medications at 
the same date. Hospitalization and emergency department visits for asthma were defined as use 
of short-acting beta2-agonists during hospital visits among asthmatic patients.
Results: There were 1,172,807 asthmatic children in 2010, which increased steadily to 
1,590,228 in 2014 in Korea. The prevalence showed an increasing trend annually for all ages. 
The mean prevalence by age in those older than 2 years decreased during the study period 
(from 39.4% in the 2–3 year age group to 2.6% in the 15–18 year age group). In an outpatient 
prescription, leukotriene receptor antagonists were the most commonly prescribed 
medication for all ages. Patients older than 6 years for whom inhaled corticosteroids were 
prescribed comprised less than 15% of asthmatic patients. The total direct medical cost for 
asthma between 2010 and 2014 ranged from $376 to $483 million. Asthma-related medical 
cost per person reached its peak in $366 in 2011 and decreased to $275 in 2014.
Conclusions: The prevalence of pediatric asthma increased annually and decreased with age. 
Individual cost of asthma showed a decreasing trend in Korean children.
Keywords: Asthma; illness burden; child; insurance claims analysis; prescription; prevalence
INTRODUCTION
Asthma is one of the most common chronic diseases in childhood. Pediatric asthma is a 
major concern because it increases the number of hospital visits and economic burden more 
than asthma in adults.1,2 In the 2000s, many studies have shown that asthma prevalence 
is increasing globally over a short period, due to the impact of environmental risk factors 
in addition to genetic factors.3,4 Some recent reports have suggested that the prevalence of 
pediatric asthma may have plateaued or declined in some developed countries.5-8 Asthma 
prevalence is changing over time and varies among countries and regions. The prevalence 
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of adult asthma in Korea has been increasing in recent decades.9 It is important to estimate 
the prevalence of asthma as time changes in an area because appropriate treatment and 
prevention strategies for pediatric asthma should be based on accurate assessment of 
prevalence and risk factors for the pediatric population.10
The National Health Insurance (NHI) claims database could provide epidemiological data and 
information for studies on health care utilization and medical expenditure. The major mechanism 
for health care financing in Korea is the NHI, which covers the entire population, because 
enrollment in the NHI is compulsory.11 The Health Insurance Review and Assessment Service 
receives the claims data of 97% of the Korean population.12 The NHI service database represents 
the entire population and can, therefore, be used as a population-based database.13 Therefore, the 
NHI enabled us to estimate the nationwide prevalence and financial burden of pediatric asthma.11
The purpose of this study was to retrospectively analyze the NHI claims database to estimate 
the prevalence of childhood asthma in Korea, prescription patterns and its economic burden. 
Furthermore, compliance with the guidelines for the treatment and prevention of pediatric 
asthma can be assessed by analyzing treatment patterns in the NHI data.
MATERIALS AND METHODS
Data source and study population
We analyzed the insurance claims records of the Korean NHI claims database from January 
2010 to December 2014. Through this retrospective population-based study, we estimated 
the prevalence of asthma in children in Korea and investigated their asthma-related health 
care utilization, prescription and test patterns. Asthmatic patients in this study were defined 
as children who were younger than 18 years who visited hospital with an asthma code of 
J45 or J46 for the principal or within 5 additional diagnoses based on the 10th Revision of 
the International Classification of Diseases. Additionally, they required a prescription for 
asthma maintenance medication such as inhaled corticosteroid (ICS), ICS/long-acting beta2-
agonist (LABA) combination inhaler or leukotriene receptor antagonist (LTRA) on the same 
date. Population data by age with health insurance were used to estimate the prevalence of 
asthma by age. In terms of hospitalization and emergency department (ED) visits for asthma, 
asthmatic patients were defined as the use of short-acting beta2-agonist (SABA) during the 
hospital visit under the asthma definition in the current study. This study was approved 
by the Institutional Review Board of Severance Hospital (protocol no. 4-2015-0891). The 
requirement for informed consent was waived due to the retrospective nature of the study.
Asthma-related medications and tests
Asthma-related medications included SABA, ICS, ICS/LABA combination inhaler, LTRA, 
aminophylline/theophylline and systemic steroids (Supplementary Table S1). Analysis of 
drug prescribing frequency in asthmatic patients only included outpatient prescriptions. 
Asthma-related tests included spirometry with/without bronchodilator and allergy tests such 
as multiple-allergen simultaneous test, serum total or allergen-specific Immunoglobulin E 
levels and skin prick test.
Asthma-related costs
In a prevalence and cost-of-illness study, the cost of an illness in a population is measured 
over a defined period, usually a year.14 The economic costs of a disease can be classified as 
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direct, indirect or intangible costs. Direct costs comprise all direct medical cost, of which 
include expenditures for diagnosis, treatment, continuing care, rehabilitation, terminal 
care for an illness15 and direct non-medical costs. Direct medical costs are defined as formal 
expenses for the diagnosis and treatment of asthma within the official health care system 
and consist of inpatient and outpatient care costs. In the current study, asthma-related 
cost was defined as the sum of the direct medical costs, which consisted of asthma-related 
hospitalizations, outpatient visits, ED visits and the costs of prescribed medications. The 
outpatient visits were divided into primary hospital, secondary hospital and tertiary hospital 
visits. Expenses not covered by insurance were excluded in the calculation. All costs were 
calculated in KRW then converted into USD using the exchange rate of 1 USD at 1,107 KRW, 
which is the average exchange rate between 2010 and 2014.
RESULTS
Asthma prevalence, asthma-related hospital visits and tests
The number of asthmatic children (from 1 month to 18 years old) on record was 1,172,807 
in 2010 and increased steadily to 1,590,228 in 2014 in Korea (Table 1). In 2014, 16,110 (male 
16,720; female 15,010) patients per 100,000 children had asthma compared to 10,780 (male 
11,370; female 9,930) patients per 100,000 in 2010 (Table 1, Supplementary Table S2). The 
annual trend of increasing prevalence was noted for all ages (Fig. 1A). Asthma prevalence 
decreased with increasing age and the peak prevalence was mostly noted in the age group 
2–4 years (33.1%–41.5%) (Fig. 1B, Table 1).
The distribution of asthma-related health service use according to age during the study period 
was investigated (Fig. 2, Supplementary Table S3). The proportions of outpatient clinic visit 
among the types of healthcare facilities increased with age (Fig. 2A, Supplementary Table S3).  
The frequency of outpatient clinic visits among children with asthma was highest in the 
2–4 years age group, and decreased with age (Fig. 2B, Supplementary Table S3). The 
proportion and frequency of ED visits decreased with age (Fig. 2, Supplementary Table S3). 
Annually, approximately 68% of children younger than 2 years visited the ED and about 18% 
of them were hospitalized at least once due to asthma (Supplementary Table S3). While 
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Table 1. Prevalence of asthma according to age
2010 2011 2012 2013 2014
Population*
Total 10,476,414 (100.00) 10,266,580 (100.00) 10,085,908 (100.00) 9,853,821 (100.00) 9,618,446 (100.00)
1 mon–2 yr 880,973 (100.00) 912,069 (100.00) 926,206 (100.00) 899,343 (100.00) 854,183 (100.00)
2–4 yr 946,479 (100.00) 901,069 (100.00) 907,557 (100.00) 936,832 (100.00) 955,750 (100.00)
4–6 yr 867,117 (100.00) 927,946 (100.00) 948,938 (100.00) 903,870 (100.00) 909,869 (100.00)
6–12 yr 3,178,694 (100.00) 3,008,608 (100.00) 2,833,814 (100.00) 2,779,081 (100.00) 2,759,627 (100.00)
12–15 yr 1,905,874 (100.00) 1,847,888 (100.00) 1,825,170 (100.00) 1,753,637 (100.00) 1,637,202 (100.00)
15–19 yr 2,697,277 (100.00) 2,668,277 (100.00) 2,644,223 (100.00) 2,581,058 (100.00) 2,501,815 (100.00)
Subjects
Total 1,172,807 (11.19) 1,428,081 (13.91) 1,518,842 (15.06) 1,499,803 (15.22) 1,590,228 (16.53)
1 mon–2 yr 233,405 (26.49) 336,236 (36.87) 307,247 (33.17) 345,706 (38.44) 351,302 (41.13)
2–4 yr 317,577 (33.55) 365,229 (40.51) 380,955 (41.98) 373,378 (39.86) 391,773 (40.99)
4–6 yr 223,874 (25.82) 254,485 (27.42) 302,400 (31.87) 279,654 (30.94) 273,866 (30.10)
6–12 yr 293,444 (9.23) 352,732 (11.72) 378,990 (13.37) 349,145 (12.56) 403,312 (14.61)
12–15 yr 54,907 (2.88) 64,217 (3.48) 76,293 (4.18) 75,049 (4.28) 83,807 (5.12)
15–19 yr 49,600 (1.84) 55,182 (2.07) 72,957 (2.76) 76,871 (2.98) 86,168 (3.44)
Values are presented as number (%).
*Number of population with health insurance by age.
both proportions decreased with increasing age, the proportion of outpatient clinic visits 
remained steady in the range 95%–99%, through all age groups (Supplementary Table S3).
Spirometry for pulmonary function test (PFT) was performed in 0.4%–5.7% of asthmatic 
patients older than 4 years and allergy test was performed in 0.9%–4.4% of them. A higher 
proportion of those for whom asthma related tests were performed were older children (Fig. 3, 
Supplementary Table S4).
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Fig. 1. Prevalence of asthma in children according to year (A) and age (B). The prevalence showed an increasing trend annually and decreased with age.
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Fig. 2. The patterns of health care service use with age. The graphs show the mean proportion (A) and numbers (B) of visits by health care service type between 
2010 and 2014. Error bars show the minimum and maximum values. 
OPD, outpatient department; ED, emergency department.
Patterns of asthma medication prescriptions
Fig. 4 shows the prescription patterns of asthma medication according to age in outpatients. 
LTRAs were the most commonly prescribed asthma medications for all ages (Fig. 4A). After 
2 years of age, the majority of asthmatic patients received prescriptions for LTRAs, and this 
proportion of patients increased with increasing age (Fig. 4B). The overall proportion of 
patients who were prescribed ICS or ICS/LABA combination inhalers was less than 15%. 
While the proportion of asthmatic children prescribed ICS decreased by age and fell to 4.2% 
in the 15–19 year age group, the proportion of patients prescribed ICS/LABA combination 
inhalers increased to 10% among those aged 18 years (Fig. 4B, Supplementary Table S5). 
The number of systemic steroid prescriptions declined with age (Fig. 4A, Supplementary 
Table S6). Systemic steroids were prescribed at least once in 25%-42% of the asthmatic 
patients and the proportion of patients for whom it was prescribed slightly decreased with 
age (Fig. 4B, Supplementary Table S5). The proportion of patients for whom xanthine 
derivatives were prescribed at least once and declined with age (Fig. 4B, Supplementary 
Table S5). Between 2010 and 2014, the proportion of patients for whom LTRAs were prescribed 
and the number of LTRA prescriptions per person increased over time for all the ages, while 
the proportion of patients for whom ICS or ICS/LABA combination inhalers were prescribed 
decreased (Fig. 4C and D, Supplementary Tables S5 and S6). The proportions of patients 
for whom xanthine derivatives were prescribed and the number of prescriptions per person 
decreased gradually during the study period (Fig. 4C and D, Supplementary Tables S5 and S6). 
There was no significant change in the number of prescribed systemic corticosteroids.
Economic burden of pediatric asthma
The direct medical costs of asthma during the years 2010–2014 are presented in 
Supplementary Table S7 and Fig. 5. While there was an increase of 35.6% (from 1,172,807 
to 1,590,228) in the number of children with asthma between 2010 and 2014, there was 
no significant increase in the annual total direct medical costs for asthma or the annual 
direct medical expenses per person decreased. The total age- and year-specific asthma-
related costs ranged from 109 USD (120,747 KRW) in the 15–19 years age group in 2013 to 
508 USD (562,747 KRW) in those aged 1 month–2 years in 2010. Over the entire 5 years, the 
mean direct medical cost per patient decreased with increasing age, from 447 USD (495,173 
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year during the study period (2010-2014). Error bars show the standard error.
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with prescribed asthma medications by age. (C) The number of prescription per person per year. (D) Percentage of asthmatic patients with prescribed asthma 
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KRW) in the age group of less-than-2-year-olds to 121 USD (134,040 KRW) in the 15-19 
years age group.
The total cost of medications prescribed for patients with asthma younger than 18 years amounted 
to 105 million USD in 2011, but declined to 70 million USD in 2014. The cost of asthma medication 
per person each year also decreased from 87 USD in 2011 to 53 USD in 2014. The total direct medical 
cost for the treatment of pediatric asthma showed a declining trend during the recent 5 years.
In terms of the proportion of composition in total direct medical costs, hospitalizations and 
ED visits made up more than half of the total cost in the age group younger than 4 years, 
while medications and hospital outpatient visits constituted the most costs in those older 
than 12 years (Fig. 5B). The total cost per person in each subcategory showed a decreasing 
trend with age and the number of ED visits and hospital admissions showed the greatest 
difference with increasing age (Supplementary Fig. S1).
DISCUSSION
We analyzed the NHI claims database to investigate the incidence, prescribing patterns and 
economic burden of pediatric asthma in Korea between 2010 and 2014. The estimation of the 
prevalence and economic burden, and analysis of prescription patterns in pediatric asthma 
are essential for evaluating the current treatment trend for pediatric asthma control.
In this study, the overall prevalence of asthma in all children younger than 18 years was 
14.3%. Previous epidemiological studies reported a lower or similar prevalence of asthma in 
Korea compared to our study.16,17
According to age, the prevalence of asthma was slightly different for each age group, but 
increased over the study period. The incidence of asthma decreased after the age of 2 years 
and was more than 20% until school age. Asthma in children younger than 2 years can be 
overdiagnosed because it is difficult to distinguish between asthma and bronchiolitis or 
other respiratory diseases presenting with wheezing other than asthma. The diagnosis of 
asthma in children younger than 5 years is predominantly clinical, since there is currently no 
satisfactory means of making an accurate diagnosis. Therefore, the diagnosis of pediatric 
asthma among children younger than 5 years can be overestimated.
The Asthma Insights and Reality surveys revealed that spirometry is rarely performed in 
children with asthma in Asia; 75% of children in Asia-Pacific countries had never undergone 
PFT.18 This study also showed a low PFT performance rate because it is difficult to perform 
spirometric measurements in the primary care settings at most of the asthmatic children 
visits. Furthermore, children younger than 6 years who have difficulty with forced inspiration 
and expiration may require encouragement from a respiratory technician or physician.
The mainstay of asthma pharmacotherapy has been the use of ICS as the first-line therapy in 
all asthmatic patients including younger children.19 In the current study, the most frequently 
prescribed asthma maintenance medication was LTRA in all age groups, even for the 15–19 
year age group. Patients older than 6 years for whom ICS-based inhalers were prescribed 
comprised less than 15% of asthma patients, which is lower than the 30% found in a 
population-based cohort study in a Dutch primary care database.20 It was thought that oral 
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LTRAs were more often prescribed than ICS-based inhalers because asthmatic children and 
parents have a higher preference for oral medications. Furthermore, there are restrictions 
on ICS prescription in outpatient clinics in Korea because it takes much time and practice to 
educate the patient about the use of the inhaler.
The leading contributors to the direct medical expenses for asthmatic children in Korea were 
hospitalization and ED visits in children younger than 4 years, accounting for more than half 
of the total direct costs. Asthmatic children younger than 2 years were more likely to visit the 
hospital and ED due to the use of asthma-related health care services. On the other hand, 
medications and primary outpatient visits accounted for about a quarter of the total direct 
costs of children older than 4 years.
The decrease in annual asthma-related costs per person was in line with decreases in drug 
prescriptions, outpatient department (OPD) visits, particularly visits to tertiary hospitals, and 
in turn, ED visits. LTRA and ICS-based inhalers prescriptions for asthma maintenance therapy 
have increased. This seems to be due to the early diagnosis and treatment of pediatric asthma 
and an increase in the incidence of mild asthma. Proper maintenance therapy for asthma can 
reduce the risk of asthmatic attacks, total drug treatment costs, and OPD or ED visits.21,22
The strength of the current study compared to other similar prior studies is that the data 
base obtained from the Korean NHI provides a unique and comprehensive opportunity to 
evaluate the prevalence of pediatric asthma because Korean NHI include most people in 
Korea. Therefore, this study is clinically relevant and significant for improved management of 
pediatric asthma based on the prior clinical services provided.
This study has several limitations. The prevalence of asthma in young children might be 
overestimated, although maintenance therapy was included for asthma diagnosis. Recent 
studies have shown that about half of children with asthma were diagnosed excessively without 
PFTs because of symptoms such as dyspnea, coughing and wheezing.23,24 On the other hand, 
the number of asthmatic patients, especially those with mild asthma not receiving maintenance 
therapy, could have been underestimated because patients with asthma included those who were 
symptomatic and for whom asthma medications were prescribed. Drug prescriptions for asthma 
guidelines could not be accurately assessed because asthmatic patients were not classified 
according to asthma severity. Finally, the medical costs can be affected by the Drug Use Review 
(DUR) system. DUR is a systematic review program for patient safety that begins in 2011 in 
Korea, which determines whether or not patients receive or prescribe appropriate medications.25
The prevalence of asthma in children younger than 18 years increased annually and decreased 
with age. PFTs were performed in less than 5% of asthmatic patients older than 4 years. LTRA 
was the most frequently prescribed medication in all age groups. During the study period, 
the total direct medical costs for the treatment and prevention of asthma in children have not 
significantly changed, but the average cost per person has decreased.
ACKNOWLEDGMENTS
This research was supported by a grant of the Korea Health Technology R&D Project through 
the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & 
Welfare, Republic of Korea (HI17C0104), by Basic Science Research Program through the National 
287https://e-aair.org https://doi.org/10.4168/aair.2019.11.2.280
Pediatric Asthma in Korea
Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning 
(NRF-2017R1A2B2004043 and NRF-2018R1A5A2025079), and by Institute for Information & 
communications Technology Promotion (IITP) grant funded by the Korea government (MSIT) 
(No. 2017-0-00599, Development of Big Data Analytics Platform for Military Health Information).
SUPPLEMENTARY MATERIALS
Supplementary Table S1
Drug substance code related to asthma
Click here to view
Supplementary Table S2
Prevalence of asthma according to age and sex
Click here to view
Supplementary Table S3
Visiting patterns of asthmatic children by the type of health service
Click here to view
Supplementary Table S4
Performance of asthma-related tests
Click here to view
Supplementary Table S5
The proportion of patients who received asthma-related medications in outpatient settings 
among asthmatic patients
Click here to view
Supplementary Table S6
The number of asthma-related medications prescribed in outpatient settings per asthma 
patient every year
Click here to view
Supplementary Table S7
Asthma-related direct medical costs (USD)
Click here to view
Supplementary Fig. S1
Asthma-related direct costs according to health care service and medication by age.
Click here to view
288https://e-aair.org https://doi.org/10.4168/aair.2019.11.2.280
Pediatric Asthma in Korea
REFERENCES
 1. Lee-Sarwar KA, Bacharier LB, Litonjua AA. Strategies to alter the natural history of childhood asthma. 
Curr Opin Allergy Clin Immunol 2017;17:139-45. 
PUBMED | CROSSREF
 2. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: 
a systematic review. BMC Pulm Med 2009;9:24. 
PUBMED | CROSSREF
 3. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract 2017;3:1. 
PUBMED | CROSSREF
 4. Chung F, Barnes N, Allen M, Angus R, Corris P, Knox A, et al. Assessing the burden of respiratory disease 
in the UK. Respir Med 2002;96:963-75. 
PUBMED | CROSSREF
 5. Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence 
of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). 
Thorax 2007;62:758-66. 
PUBMED | CROSSREF
 6. Kälvesten L, Bråbäck L. Time trend for the prevalence of asthma among school children in a Swedish 
district in 1985–2005. Acta Paediatr 2008;97:454-8. 
PUBMED | CROSSREF
 7. Lee YL, Hwang BF, Lin YC, Guo YL; Taiwan Childhood Allergy Survey Group. Time trend of asthma 
prevalence among school children in Taiwan. Pediatr Allergy Immunol 2007;18:188-95. 
PUBMED | CROSSREF
 8. Schröder PC, Li J, Wong GW, Schaub B. The rural-urban enigma of allergy: what can we learn from studies 
around the world? Pediatr Allergy Immunol 2015;26:95-102. 
PUBMED | CROSSREF
 9. Park SY, Kim JH, Kim HJ, Seo B, Kwon OY, Chang HS, et al. High prevalence of asthma in elderly women: 
findings from a Korean national health database and adult asthma cohort. Allergy Asthma Immunol Res 
2018;10:387-96. 
PUBMED | CROSSREF
 10. Lee SI. Prevalence of childhood asthma in Korea: International Study of Asthma and Allergies in 
childhood. Allergy Asthma Immunol Res 2010;2:61-4. 
PUBMED | CROSSREF
 11. Kwon S. Payment system reform for health care providers in Korea. Health Policy Plan 2003;18:84-92. 
PUBMED | CROSSREF
 12. Koo BK, Lee JH, Kim J, Jang EJ, Lee CH. Prevalence of gestational diabetes mellitus in Korea: a National 
Health Insurance database study. PLoS One 2016;11:e0153107. 
PUBMED | CROSSREF
 13. Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, et al. Background and data configuration 
process of a nationwide population-based study using the Korean national health insurance system. 
Diabetes Metab J 2014;38:395-403. 
PUBMED | CROSSREF
 14. Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin Immunol 2001;107 
Suppl:S445-8. 
PUBMED | CROSSREF
 15. Saha S, Gerdtham UG. Cost of illness studies on reproductive, maternal, newborn, and child health: a 
systematic literature review. Health Econ Rev 2013;3:24. 
PUBMED | CROSSREF
 16. Jang Y, Shin A. Sex-based differences in asthma among preschool and school-aged children in Korea. 
PLoS One 2015;10:e0140057. 
PUBMED | CROSSREF
 17. Kim BK, Kim JY, Kang MK, Yang MS, Park HW, Min KU, et al. Allergies are still on the rise? A 6-year 
nationwide population-based study in Korea. Allergol Int 2016;65:186-91. 
PUBMED | CROSSREF
 18. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control 
of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 
2004;114:40-7. 
PUBMED | CROSSREF
289https://e-aair.org https://doi.org/10.4168/aair.2019.11.2.280
Pediatric Asthma in Korea
 19. Global Initiative for Asthma (GINA). Diagnosis and management of asthma in children 5 years and 
younger 2015 [Internet]. [place unknown]: Global Initiative for Asthma; 2015 [cited 2017 Jan 30]. 
Available from: http://ginasthma.org.
 20. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Prescription patterns, 
adherence and characteristics of non-adherence in children with asthma in primary care. Pediatr Allergy 
Immunol 2016;27:201-8. 
PUBMED | CROSSREF
 21. Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National surveillance of 
asthma: United States, 2001–2010. Vital Health Stat 3 2012:1-58.
PUBMED
 22. Klok T, Kaptein AA, Duiverman EJ, Brand PL. High inhaled corticosteroids adherence in childhood 
asthma: the role of medication beliefs. Eur Respir J 2012;40:1149-55. 
PUBMED | CROSSREF
 23. Yang CL, Simons E, Foty RG, Subbarao P, To T, Dell SD. Misdiagnosis of asthma in schoolchildren. 
Pediatr Pulmonol 2017;52:293-302. 
PUBMED | CROSSREF
 24. Looijmans-van den Akker I, van Luijn K, Verheij T. Overdiagnosis of asthma in children in primary care: a 
retrospective analysis. Br J Gen Pract 2016;66:e152-7. 
PUBMED | CROSSREF
 25. Yang JH, Kim M, Park YT, Lee EK, Jung CY, Kim S. The effect of the introduction of a nationwide DUR 
system where local DUR systems are operating--the Korean experience. Int J Med Inform 2015;84:912-9. 
PUBMED | CROSSREF
290https://e-aair.org https://doi.org/10.4168/aair.2019.11.2.280
Pediatric Asthma in Korea
